873 related articles for article (PubMed ID: 33779742)
1. Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials.
Tabrizi S; Trippa L; Cagney D; Aizer AA; Tanguturi S; Ventz S; Fell G; Bellon JR; Mamon H; Nguyen PL; D'Amico AV; Haas-Kogan D; Alexander BM; Rahman R
JAMA Netw Open; 2021 Mar; 4(3):e213304. PubMed ID: 33779742
[TBL] [Abstract][Full Text] [Related]
2. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
3. Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer: A Meta-analysis of Randomized Noninferiority Trials.
Royce TJ; Lee DH; Keum N; Permpalung N; Chiew CJ; Epstein S; Pluchino KM; D'Amico AV
Eur Urol Focus; 2019 Jul; 5(4):577-584. PubMed ID: 29221876
[TBL] [Abstract][Full Text] [Related]
4. Differential Use of Radiotherapy Fractionation Regimens in Prostate Cancer.
Qureshy SA; Diven MA; Ma X; Marciscano AE; Hu JC; McClure TD; Barbieri C; Nagar H
JAMA Netw Open; 2023 Oct; 6(10):e2337165. PubMed ID: 37815829
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
6. Breast, Prostate, and Rectal Cancer: Should 5-5-5 Be a New Standard of Care?
Ling DC; Vargo JA; Beriwal S
Int J Radiat Oncol Biol Phys; 2020 Oct; 108(2):390-393. PubMed ID: 32890517
[No Abstract] [Full Text] [Related]
7. Radiation treatment of hemato-oncological patients in times of the COVID-19 pandemic : Expert recommendations from the radiation oncology panels of the German Hodgkin Study Group and the German Lymphoma Alliance.
Oertel M; Elsayad K; Engenhart-Cabillic R; Reinartz G; Baues C; Schmidberger H; Vordermark D; Marnitz S; Lukas P; Ruebe C; Engert A; Lenz G; Eich HT
Strahlenther Onkol; 2020 Dec; 196(12):1096-1102. PubMed ID: 33125504
[TBL] [Abstract][Full Text] [Related]
8. Moderate hypofractionation remains the standard of care for whole-breast radiotherapy in breast cancer: Considerations regarding FAST and FAST-Forward.
Krug D; Baumann R; Combs SE; Duma MN; Dunst J; Feyer P; Fietkau R; Haase W; Harms W; Hehr T; Piroth MD; Sedlmayer F; Souchon R; Strnad V; Budach W;
Strahlenther Onkol; 2021 Apr; 197(4):269-280. PubMed ID: 33507331
[TBL] [Abstract][Full Text] [Related]
9. Utilization of Hypofractionated Whole-Breast Radiotherapy With Concurrent Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy.
Sayan M; Vergalasova I; Jhawar S; Kumar S; George M; Kowzun M; Potdevin L; Toppmeyer D; Haffty B; Ohri N
Clin Breast Cancer; 2021 Feb; 21(1):31-36. PubMed ID: 32792224
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
Huang SH; O'Sullivan B; Su J; Ringash J; Bratman SV; Kim J; Hosni A; Bayley A; Cho J; Giuliani M; Hope A; Spreafico A; Hansen AR; Siu LL; Gilbert R; Irish JC; Goldstein D; de Almeida J; Tong L; Xu W; Waldron J
Cancer; 2020 Aug; 126(15):3426-3437. PubMed ID: 32478895
[TBL] [Abstract][Full Text] [Related]
11. Partial breast irradiation for early breast cancer.
Lehman M; Hickey BE; Francis DP; See AM
Cochrane Database Syst Rev; 2014 Jun; (6):CD007077. PubMed ID: 24938937
[TBL] [Abstract][Full Text] [Related]
12. A Quantitative Framework for Modeling COVID-19 Risk During Adjuvant Therapy Using Published Randomized Trials of Glioblastoma in the Elderly.
Tabrizi S; Trippa L; Cagney D; Tanguturi S; Ventz S; Fell G; Wen PY; Alexander BM; Rahman R
Neuro Oncol; 2020 Apr; 22(7):918-27. PubMed ID: 32339235
[TBL] [Abstract][Full Text] [Related]
13. Managing patient flows in radiation oncology during the COVID-19 pandemic : Reworking existing treatment designs to prevent infections at a German hot spot area University Hospital.
Akuamoa-Boateng D; Wegen S; Ferdinandus J; Marksteder R; Baues C; Marnitz S
Strahlenther Onkol; 2020 Dec; 196(12):1080-1085. PubMed ID: 33123776
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of hypofractionation for primary management of prostate cancer.
Koontz BF; Bossi A; Cozzarini C; Wiegel T; D'Amico A
Eur Urol; 2015 Oct; 68(4):683-91. PubMed ID: 25171903
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated Adjuvant Radiation Therapy Is Effective for Patients With Lymph Node-Positive Breast Cancer: A Population-Based Analysis.
Koulis TA; Nichol AM; Truong PT; Speers C; Gondara L; Tyldesley S; Lohrisch C; Weir L; Olson RA
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1150-1158. PubMed ID: 32721421
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization.
Chodick G; Tene L; Patalon T; Gazit S; Ben Tov A; Cohen D; Muhsen K
JAMA Netw Open; 2021 Jun; 4(6):e2115985. PubMed ID: 34097044
[TBL] [Abstract][Full Text] [Related]
17. Increasing Use of Shorter-Course Radiotherapy for Prostate Cancer.
Yu JB; Sun Y; Jia AY; Vince RA; Shoag JE; Zaorsky NG; Spratt DE
JAMA Oncol; 2023 Dec; 9(12):1696-1701. PubMed ID: 37796479
[TBL] [Abstract][Full Text] [Related]
18. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
19. Impact of the COVID-19 pandemic on brachytherapy and cancer patient outcomes: A systematic review.
Parikh S; Zhang Y; Sherwani Z; Kumar R; Ohri N; Jan I; Vergalasova I; Jabbour S; Hathout L
Brachytherapy; 2024; 23(2):141-148. PubMed ID: 38307787
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 and radiotherapy: potential new strategies for patients management with hypofractionation and telemedicine.
Di Franco R; Borzillo V; D'Ippolito E; Scipilliti E; Petito A; Facchini G; Berretta M; Muto P
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12480-12489. PubMed ID: 33336767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
